<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1405-9940</journal-id>
<journal-title><![CDATA[Archivos de cardiología de México]]></journal-title>
<abbrev-journal-title><![CDATA[Arch. Cardiol. Méx.]]></abbrev-journal-title>
<issn>1405-9940</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Cardiología Ignacio Chávez]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1405-99402016000200163</article-id>
<article-id pub-id-type="doi">10.1016/j.acmx.2015.12.002</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Colesterol y aterosclerosis. Consideraciones históricas y tratamiento]]></article-title>
<article-title xml:lang="en"><![CDATA[Cholesterol and atherosclerosis. Historical considerations and treatment]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Zárate]]></surname>
<given-names><![CDATA[Arturo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Manuel-Apolinar]]></surname>
<given-names><![CDATA[Leticia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Basurto]]></surname>
<given-names><![CDATA[Lourdes]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[De la Chesnaye]]></surname>
<given-names><![CDATA[Elsa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Saldívar]]></surname>
<given-names><![CDATA[Iván]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Centro Médico Nacional ]]></institution>
<addr-line><![CDATA[México DF]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="A02">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Centro Médico Nacional ]]></institution>
<addr-line><![CDATA[México DF]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2016</year>
</pub-date>
<volume>86</volume>
<numero>2</numero>
<fpage>163</fpage>
<lpage>169</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1405-99402016000200163&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1405-99402016000200163&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1405-99402016000200163&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El colesterol es un esteroide precursor de hormonas, componente esencial de la membrana celular, sin embargo, alteraciones en la regulación de la síntesis, absorción y excreción del colesterol predisponen al desarrollo de enfermedades cardiovasculares de origen aterosclerótico. De esta manera, reconociendo los acontecimientos históricos desde hace 200 años, con Michel Chevreul que le dio el nombre "colesterina", más tarde Lobstein que acuñó el término aterosclerosis y Marchand que lo introduce, Anichkov que identifica el colesterol en las placas de ateroma, y el descubrimiento del receptor LDL por Brown y Goldstein; además de la aparición de los diferentes fármacos que han surgido desde los fibratos, las estatinas y en esta década cetrapibs, muy prometedores para aumentar el HDL, en forma más reciente, ezetimibe y anti-PCSK9 para inhibir el proceso de degradación del receptor LDL; no obstante, estos avances no han sido suficientes para disminuir la morbilidad en enfermedades cardiovasculares.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Cholesterol is a precursor of steroid hormones and an essential component of the cell membrane, however, altered regulation of the synthesis, absorption and excretion of cholesterol predispose to cardiovascular diseases of atherosclerotic origin. Despite, the recognition of historical events for 200 years, starting with Michel Chevreul naming "cholesterol"; later on, Lobstein coining the term atherosclerosis and Marchand introducing it, Anichkov identifying cholesterol in atheromatous plaque, and Brown and Goldstein discovering LDL receptor; as well as the emerging of different drugs, such as fibrates, statins and cetrapibs this decade, promising to increase HDL and the most recent ezetimibe and anti-PCSK9 to inhibit the degradation of LDL receptor, however morbidity has not been reduced in cardiovascular disease.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Colesterol]]></kwd>
<kwd lng="es"><![CDATA[Aterosclerosis]]></kwd>
<kwd lng="es"><![CDATA[Enfermedad cardiovascular]]></kwd>
<kwd lng="es"><![CDATA[Estatinas]]></kwd>
<kwd lng="es"><![CDATA[Hipercolesterolemia]]></kwd>
<kwd lng="es"><![CDATA[México]]></kwd>
<kwd lng="en"><![CDATA[Cholesterol]]></kwd>
<kwd lng="en"><![CDATA[Atherosclerosis]]></kwd>
<kwd lng="en"><![CDATA[Cardiovascular disease]]></kwd>
<kwd lng="en"><![CDATA[Statins]]></kwd>
<kwd lng="en"><![CDATA[Hypercholesterolemia]]></kwd>
<kwd lng="en"><![CDATA[Mexico]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The biosynthetic pathway for cholesterol]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kresge]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Simoni]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hill]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[J Biol Chem]]></source>
<year>2005</year>
<volume>280</volume>
<page-range>135-7</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Ueber der gehalt normaler und atheromatoser aorten and cholesterol und cholesterinester]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Windaus]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Z Phys Chem]]></source>
<year>1910</year>
<volume>67</volume>
<page-range>174-82</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Desarrollo histórico de la aterosclerosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Romero]]></surname>
<given-names><![CDATA[GE]]></given-names>
</name>
</person-group>
<source><![CDATA[Opcion Med]]></source>
<year>2012</year>
<volume>2</volume>
<page-range>24-30</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Brown and Goldstein The cholesterol chronicles]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prashant]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[PNAS]]></source>
<year>2013</year>
<volume>110</volume>
<page-range>14829-32</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Rememorando la contribución de Goldstein y Brown al estudio del metabolismo del colesterol a un cuarto de siglo del Premio Nobel de Medicina]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cortés]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Vásquez]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Arteaga]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Med Chile]]></source>
<year>2012</year>
<volume>140</volume>
<page-range>1053-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A historical perspective on the discovery of statins]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Endo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Proc Jpn Acad Ser B]]></source>
<year>2010</year>
<volume>86</volume>
<page-range>484-93</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The searching discover of statins and the Lasker Prize]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zárate]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Basurto]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Saucedo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Med IMSS]]></source>
<year>2009</year>
<volume>47</volume>
<page-range>119-20</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Discovery of the lipoproteins, their role in fat transport and their significance as risk factors]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olso]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[J Nutr]]></source>
<year>1998</year>
<volume>128</volume>
<page-range>439S-43S</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Discovery of the cellular and molecular basic of cholesterol control]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schekman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[PNAS]]></source>
<year>2013</year>
<volume>110</volume>
<page-range>14833-6</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Ueber die wirking der tiershen einwesses auf der aorta]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ignatowsky]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
</person-group>
<source><![CDATA[Virchows Archiv]]></source>
<year>1909</year>
<volume>198</volume>
<page-range>248-52</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Terapia de reemplazo hormonal con estradiol transdérmico disminuye los niveles de insulina-cortisol y lipoproteínas en mujeres posmenopáusicas]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Basurto]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Saucedo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ochoa]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Ginecol Obstet Mex]]></source>
<year>2002</year>
<volume>70</volume>
<page-range>491-5</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Pathology of the vulnerable plaque]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Virmani]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Burke]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Farb]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2006</year>
<volume>47</volume>
<page-range>17-38</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Evaluación no invasiva de la función endotelial en la práctica clínica]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arrebola]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Laclaustra]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kaski]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2012</year>
<volume>65</volume>
<page-range>80-90</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Disfunción endotelial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Badimón]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Esp Cardiol Supl]]></source>
<year>2006</year>
<volume>6</volume>
<page-range>21A-30A</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Leptin mediated ObRb receptor increases expression of adhesion intercellular molecules and Colesterol y aterosclerosis Consideraciones históricas y tratamiento 169 cyclooxygenase 2 on murine aorta tissue inducing endothelial dysfunction]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Manuel]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Zárate]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Clin Exp Med]]></source>
<year>2013</year>
<volume>6</volume>
<page-range>192-6</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cholesterol metabolism and immunity]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simon]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2014</year>
<volume>371</volume>
<page-range>1933-5</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Ectopic fat in insulin resistance dislipidemia and cardiometabolic disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shulman]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2014</year>
<volume>371</volume>
<page-range>1131-41</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Situación actual del tratamiento de las dislipidemias en España]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[GI]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Esp Cardiol Supl]]></source>
<year>2012</year>
<volume>12</volume>
<page-range>2-7</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[New perspectives on the use of niacin in the treatment of lipid disorders]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[McKenney]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Arch Intern Med]]></source>
<year>2004</year>
<volume>164</volume>
<page-range>697-705</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds A meta-analysis of randomized controlled trials]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Birjmohun]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Hutten]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Kastelein]]></surname>
<given-names><![CDATA[JJP]]></given-names>
</name>
</person-group>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2005</year>
<volume>45</volume>
<page-range>185-97</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cardiovascular disease with diabetes or the metabolic syndrome Should statins or fibrates be first line of therapy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robins]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Curr Opin Lipidol]]></source>
<year>2003</year>
<volume>14</volume>
<page-range>575-83</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The influence of dysfunctional signaling and lipid homeostasis in mediating the inflammatory responses during atherosclerosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buckley]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Dipak]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
</person-group>
<source><![CDATA[Biochim Biophys Acta]]></source>
<year>2015</year>
<volume>1852</volume>
<page-range>1498-510</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[El tratamiento del colesterol alterado en una encrucijada terapéutica]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zárate]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Saucedo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Basurto]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Med IMSS]]></source>
<year>2012</year>
<volume>50</volume>
<page-range>1-4</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efecto de un anticuerpo monoclonal anti PCSK9 sobre LDL]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bailen]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Clin Esp]]></source>
<year>2012</year>
<volume>212</volume>
<page-range>408-9</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effect of a monoclonal antibody to PCSK9 on LDL cholesterol]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stein]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Mellis]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yancopoulos]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2012</year>
<volume>366</volume>
<page-range>1108-18</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effect of torcetrapib on the progression of coronary atherosclerosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nissen]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Tardif]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Nicholls]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2007</year>
<volume>356</volume>
<page-range>1304-16</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Viñeetas terapéuticas ezetimiba/simvastatina (Vytorin) para hipercolesterolemia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zárate]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Acta Médica]]></source>
<year>2006</year>
<volume>4</volume>
<page-range>215</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Conmoción causada por estudios recientes con el uso de vytorin y zetia para tratamiento del colesterol elevado y prevención de aterosclerosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zárate]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Acta Med]]></source>
<year>2009</year>
<volume>7</volume>
<page-range>232</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Proof that lower is better LDL cholesterol and IMPROVET-IT]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jarcho]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Keanay]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2015</year>
<volume>372</volume>
<page-range>2448-9</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
